Abstract |
CD40/ CD40L signaling promotes both B cell and CTL responses in vivo, the latter being beneficial in tumor models. Because CTL may also limit autoreactive B cell expansion in lupus, we asked whether an agonist CD40 mAb would exacerbate lupus due to B cell stimulation or would improve lupus due to CTL promotion. These studies used an induced model of lupus, the parent-into-F1 model in which transfer of DBA/2 splenocytes into B6D2F1 mice induces chronic lupus-like graft-vs-host disease (GVHD). Although agonist CD40 mAb treatment of DBA-->F1 mice initially exacerbated B cell expansion, it also strongly promoted donor CD8 T cell engraftment and cytolytic activity such that by 10 days host B cells were eliminated consistent with an accelerated acute GVHD. CD40 stimulation bypassed the requirement for CD4 T cell help for CD8 CTL possibly by licensing dendritic cells (DC) as shown by the following: 1) greater initial activation of donor CD8 T cells, but not CD4 T cells; 2) earlier activation of host DC; 3) host DC expansion that was CD8 dependent and CD4 independent; and 4) induction of acute GVHD using CD4-depleted purified DBA CD8+ T cells. A single dose of CD40 mAb improved lupus-like renal disease at 12 wk, but may not suffice for longer periods consistent with a need for continuing CD8 CTL surveillance. These results demonstrate that in the setting of lupus-like CD4 T cell-driven B cell hyperactivity, CTL promotion is both feasible and beneficial and the CTL-promoting properties of CD40 stimulation outweigh the B cell-stimulatory properties.
|
Authors | Roman Puliaev, Irina Puliaeva, Lisbeth A Welniak, Abigail E Ryan, Mark Haas, William J Murphy, Charles S Via |
Journal | Journal of immunology (Baltimore, Md. : 1950)
(J Immunol)
Vol. 181
Issue 1
Pg. 47-61
(Jul 01 2008)
ISSN: 0022-1767 [Print] United States |
PMID | 18566369
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antibodies, Monoclonal
- CD40 Antigens
|
Topics |
- Animals
- Antibodies, Monoclonal
(immunology, therapeutic use)
- B-Lymphocytes
(immunology)
- CD4-Positive T-Lymphocytes
(immunology)
- CD40 Antigens
(agonists, immunology)
- Cells, Cultured
- Cytotoxicity, Immunologic
(immunology)
- Dendritic Cells
(immunology)
- Disease Models, Animal
- Graft vs Host Disease
(drug therapy, immunology)
- Lupus Erythematosus, Systemic
(immunology)
- Lymphocyte Activation
(immunology)
- Male
- Mice
- Phenotype
- T-Lymphocytes, Cytotoxic
(immunology)
- Time Factors
|